Topic: neurological disorders
A cocktail of drugs known as adrenergic receptor antagonists normalized brain potassium levels and restored movement in mice.
Roche and partner PTC Therapeutics are the latest companies to show their hand in improving kids’ ability to move with spinal muscular atrophy.
Skyhawk Therapeutics is teaming up with Takeda to develop small molecules that correct RNA mis-splicing in neurodegenerative disease.
ALS patients on the highest dose of Biogen's tofersen (BIIB067) showed a slowdown in the progression of symptoms in a phase 1 trial.
The ion channel-based chemogenetic platform involves pairing cell surface proteins with Chantix to selectively control neuronal activities.
The deal sees Neurocrine commit to $1.7 billion in milestones in return for Parkinson’s disease program VY-AADC and other assets.
Roche's Omar Khwaja, M.D., Ph.D., will become chief medical officer at gene therapy specialist Voyager Therapeutics.
Seer emerged from stealth with $36 million to develop early-warning blood tests for cancer and neurological diseases that query the body’s proteome.
The trial found the histamine type 4 receptor antagonist had no effect on vigilance and cognitive performance.
Eisai and University College London are moving their first candidate into the clinic: a tau-targeting monoclonal antibody for Alzheimer’s disease.